Drug is indicated for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy.
Gail M. Wilkes, MS, RNC
Advertisement
Articles by Gail M. Wilkes, MS, RNC
Advertisement
Latest Updated Articles
Romidepsin, an HDAC Inhibitor for Cutaneous T-cell LymphomaPublished: July 9th 2010 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
2
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
3
Quarter Century Update: Platform Approaches and Industry Investment
4
